NASDAQ : CAMP

Camp4 Therapeutics Corporation — Company profile

Healthcare · Biotechnology · United States

Last price 3.9 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 244.74M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Details

NameCamp4 Therapeutics Corporation
SectorHealthcare
IndustryBiotechnology
Employees48
Founded2016
Ipo Date2024-10-11
CeoJoshua Mandel-Brehm
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price11.00
IsinUS13463J1016
Cusip13463J101
Cik1736730
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Joshua Mandel-BrehmChief Executive Officer, President and Director
Dr. Richard A. Young Ph.D.Founder and Independent Director
Kelly GoldChief Financial Officer
Dr. Yuri Maricich M.B.A., M.D.Chief Medical Officer
Dr. Leonard I. Zon M.D.Founder and Chairman of Scientific Advisory Board
Caleb MooreChief Business Operations Officer
Dr. Daniel Tardiff Ph.D.Chief Scientific Officer
Michelle GatesSenior Vice President and Chief People Officer
Alla Sigova Ph.D.Senior Vice President of Platform
Dr. Satya Kuchimanchi Ph.D.Senior Vice President of Technical Operations

Contact

AddressOne Kendall Square, 3rd Floor, Cambridge, Massachusetts 02139, United States
Phone617 651 8867
Websitehttps://www.camp4tx.com